Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BPSC-1001 Ebola Vaccine in Healthy Adults
NCT02374385Phase 1Completed
- Sponsor
- Dalhousie University
- Start
- Nov 2014
- Primary completion
- Mar 2015
- Modality
- Viral Vector Vaccines
01
Overview
Phase 1, randomised, double-blind trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (4 arms), sponsored by Dalhousie University. Primary endpoints: Frequency and severity of local injection site reactogenicity signs and symptoms at 2 months, Frequency of adverse events (AEs) at 2 months and 2 more. Started Nov 2014; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02374385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02374385.